MedinCell S.A. (EPA:MEDCL)
France · Delayed Price · Currency is EUR 25.46
-0.48 (-1.85%)
Aug 3, 2026, 3:12 PM CET
MedinCell Cash Flow Statement
Financials in millions EUR. Fiscal year is April - March.
Millions EUR. Fiscal year is Apr - Mar.
Operating Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | -31.29 | -18.44 | -25.04 | -32.01 | -24.81 |
Depreciation & Amortization | 1.82 | 1.99 | 1.72 | 1.67 | 1.52 |
Stock-Based Compensation | 5.21 | 2.96 | 2.81 | 2.28 | 2.39 |
Other Adjustments | 9.48 | 8.58 | 5.5 | 10.1 | 1.9 |
Change in Receivables | -1.35 | -0.89 | -0.16 | -1.29 | 0.08 |
Changes in Accounts Payable | -0.61 | 2.15 | -2.33 | 1.2 | 0.03 |
Changes in Income Taxes Payable | -0.02 | -0.16 | -0.09 | - | - |
Changes in Other Operating Activities | -7.81 | 23.28 | 5.67 | -2.94 | -2.48 |
Operating Cash Flow | -24.55 | 19.47 | -11.92 | -21.01 | -21.36 |
Operating Cash Flow Growth | - | - | - | - | - |
Investing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Capital Expenditures | -0.82 | -0.75 | -0.32 | -0.58 | -1.62 |
Sale of Property, Plant & Equipment | - | - | 0 | 0.05 | 0.02 |
Purchases of Intangible Assets | -1.23 | -0.91 | -0.87 | -0.45 | -0.35 |
Other Investing Activities | -8.46 | -11.55 | 0.58 | 2.28 | 1.64 |
Investing Cash Flow | -10.51 | -13.21 | -0.61 | 1.3 | -0.32 |
Financing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Long-Term Debt Issued | 0.57 | - | 13.84 | 29.98 | 3.31 |
Long-Term Debt Repaid | -4.65 | -4.11 | -8.77 | -24.15 | -2.31 |
Net Long-Term Debt Issued (Repaid) | -4.08 | -4.11 | 5.08 | 5.83 | 1 |
Issuance of Common Stock | 45.47 | 39.74 | 23.32 | 0.5 | 0.05 |
Repurchase of Common Stock | 0.04 | 0.09 | -0.03 | 0.31 | -0.19 |
Net Common Stock Issued (Repurchased) | 45.51 | 39.84 | 23.3 | 0.81 | -0.14 |
Other Financing Activities | -2.61 | -2.41 | -2.84 | -5.08 | -1.66 |
Financing Cash Flow | 38.82 | 33.32 | 25.53 | 1.56 | -0.8 |
Net Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Foreign Exchange Rate Adjustments | -0 | - | - | - | - |
Net Cash Flow | 3.75 | 39.58 | 12.99 | -18.15 | -22.48 |
Free Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -25.37 | 18.72 | -12.25 | -21.58 | -22.99 |
Free Cash Flow Growth | - | - | - | - | - |
FCF Margin | -129.98% | 73.64% | -135.59% | -218.23% | -275.67% |
Free Cash Flow Per Share | -0.76 | 0.63 | -0.43 | -0.86 | -0.92 |
Levered Free Cash Flow | -42.8 | 3.97 | -15.32 | -26.84 | -26.36 |
Unlevered Free Cash Flow | -32.91 | 13.25 | -19.33 | -24.7 | -22.13 |